Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent or Persistent Endometrial Carcinoma Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Interventions
Cediranib Maleate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
87
States / cities
Burbank, California • Mountain View, California • Hartford, Connecticut + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Endometrial Cancer
Interventions
Avelumab, Talazoparib, Axitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Pembrolizumab, IMGN853
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced May 22, 2026, 2:49 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer
Interventions
everolimus and letrozole
Drug
Lead sponsor
Sinai Hospital of Baltimore
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced May 22, 2026, 2:49 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sodium Cridanimod, progestin therapy
Drug
Lead sponsor
Xenetic Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Burbank, California • Irvine, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IV Endometrial Carcinoma
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced May 22, 2026, 2:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced May 22, 2026, 2:49 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer
Interventions
IMGN853
Drug
Lead sponsor
Alessandro Santin
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometrial Cancer, Recurrent Endometrial Cancer
Interventions
LY3023414
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate, Temsirolimus
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
108
States / cities
Burbank, California • Palo Alto, California • San Diego, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Adenocarcinoma, ERBB2 Gene Amplification, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Trastuzumab
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Bevacizumab, Atezolizumab
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
762
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 482 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Neoplasms, Endometrial, Endometrial Cancer
Interventions
topotecan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions
stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies
Radiation · Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Uterine Corpus Carcinoma
Interventions
Gefitinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced May 22, 2026, 2:49 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
293
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer
Interventions
irofulven
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
39
States / cities
Birmingham, Alabama • Los Gatos, California • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced May 22, 2026, 2:49 AM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Enfortumab Vedotin
Drug
Lead sponsor
William Bradley
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer
Interventions
raloxifene
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced May 22, 2026, 2:49 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions
Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
583
States / cities
Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 370 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma
Interventions
ziv-aflibercept
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
67
States / cities
Hartford, Connecticut • New Britain, Connecticut • Washington D.C., District of Columbia + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced May 22, 2026, 2:49 AM EDT